173 related articles for article (PubMed ID: 35235245)
1. Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairment.
Sulkowski M; Telep LE; Colombo M; Durand F; Reddy KR; Lawitz E; Bourlière M; Cheinquer N; Scherbakovsky S; Ni L; Force L; Ramroth H; Gaggar A; Chokkalingam AP; Sise ME
Aliment Pharmacol Ther; 2022 May; 55(9):1169-1178. PubMed ID: 35235245
[TBL] [Abstract][Full Text] [Related]
2. Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD.
Sise ME; Backman E; Ortiz GA; Hundemer GL; Ufere NN; Chute DF; Brancale J; Xu D; Wisocky J; Lin MV; Kim AY; Thadhani R; Chung RT
Clin J Am Soc Nephrol; 2017 Oct; 12(10):1615-1623. PubMed ID: 28882857
[TBL] [Abstract][Full Text] [Related]
3. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals.
Liu CH; Lee MH; Lin JW; Liu CJ; Su TH; Tseng TC; Chen PJ; Chen DS; Kao JH
J Hepatol; 2020 May; 72(5):839-846. PubMed ID: 31790766
[TBL] [Abstract][Full Text] [Related]
4. Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR).
Huang CF; Tseng KC; Cheng PN; Hung CH; Lo CC; Peng CY; Bair MJ; Yeh ML; Chen CH; Lee PL; Lin CY; Kuo HT; Chen CT; Yang CC; Huang JF; Tai CM; Hu JT; Lin CL; Su WW; Tsai WL; Huang YH; Cheng CY; Lin CL; Wang CC; Yang SS; Mo LR; Chen GY; Chang CC; Wang SJ; Huang CS; Hsieh TY; Lin CW; Lee TH; Chong LW; Huang CW; Chang SN; Tsai MC; Hsu SJ; Kao JH; Liu CJ; Liu CH; Lin HC; Lee MH; Tsai PC; Dai CY; Chuang WL; Chen CY; Yu ML
Clin Gastroenterol Hepatol; 2022 May; 20(5):1151-1162.e6. PubMed ID: 34333150
[TBL] [Abstract][Full Text] [Related]
5. Acute interstitial nephritis following treatment with direct-acting antiviral agents in hepatitis C virus-infected patients: A case series.
Duque JC; Dejman A; Venkat V; Hernandez M; Roth D; Ladino MA
Clin Nephrol; 2021 Jan; 95(1):22-27. PubMed ID: 32909545
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function.
Shin HP; Park JA; Burman B; Kozarek RA; Siddique A
Clin Mol Hepatol; 2017 Dec; 23(4):316-322. PubMed ID: 28827512
[TBL] [Abstract][Full Text] [Related]
7. Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease.
Sise ME; McQuaid T; Martin P
Nephrol Dial Transplant; 2022 Nov; 37(12):2327-2334. PubMed ID: 33848334
[TBL] [Abstract][Full Text] [Related]
8. Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study.
D'Ambrosio R; Pasulo L; Giorgini A; Spinetti A; Messina E; Fanetti I; Puoti M; Aghemo A; Viganò P; Vinci M; Menzaghi B; Lombardi A; Pan A; Pigozzi MG; Grossi P; Lazzaroni S; Spinelli O; Invernizzi P; Maggiolo F; Terreni N; Monforte AD; Poggio PD; Taddei MT; Colombo S; Pozzoni P; Molteni C; Brocchieri A; Bhoori S; Buscarini E; Centenaro R; Mendeni M; Colombo AE; Di Marco M; Dionigi E; Bella D; Borghi M; Zuin M; Zaltron S; Noventa F; Annalisa S; Lampertico P; Fagiuoli S
Dig Liver Dis; 2020 Feb; 52(2):190-198. PubMed ID: 31813755
[TBL] [Abstract][Full Text] [Related]
9. Associations Between Weight Loss, Kidney Function Decline, and Risk of ESRD in the Chronic Kidney Disease in Children (CKiD) Cohort Study.
Ku E; Kopple JD; McCulloch CE; Warady BA; Furth SL; Mak RH; Grimes BA; Mitsnefes M
Am J Kidney Dis; 2018 May; 71(5):648-656. PubMed ID: 29132947
[TBL] [Abstract][Full Text] [Related]
10. Cognitive Impairment and Progression of CKD.
Kurella Tamura M; Yaffe K; Hsu CY; Yang J; Sozio S; Fischer M; Chen J; Ojo A; DeLuca J; Xie D; Vittinghoff E; Go AS;
Am J Kidney Dis; 2016 Jul; 68(1):77-83. PubMed ID: 26972681
[TBL] [Abstract][Full Text] [Related]
11. Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min.
Goel A; Bhadauria DS; Kaul A; Verma P; Mehrotra M; Gupta A; Sharma RK; Rai P; Aggarwal R
Nephrology (Carlton); 2019 Mar; 24(3):316-321. PubMed ID: 29327401
[TBL] [Abstract][Full Text] [Related]
12. Kidney Function Decline in Patients with CKD and Untreated Hepatitis C Infection.
Tartof SY; Hsu JW; Wei R; Rubenstein KB; Hu H; Arduino JM; Horberg M; Derose SF; Qian L; Rodriguez CV
Clin J Am Soc Nephrol; 2018 Oct; 13(10):1471-1478. PubMed ID: 30242027
[TBL] [Abstract][Full Text] [Related]
13. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.
Black C; Sharma P; Scotland G; McCullough K; McGurn D; Robertson L; Fluck N; MacLeod A; McNamee P; Prescott G; Smith C
Health Technol Assess; 2010 Apr; 14(21):1-184. PubMed ID: 20441712
[TBL] [Abstract][Full Text] [Related]
14. Patient Management and Clinical Outcomes Associated with a Recorded Diagnosis of Stage 3 Chronic Kidney Disease: The REVEAL-CKD Study.
Tangri N; Peach EJ; Franzén S; Barone S; Kushner PR
Adv Ther; 2023 Jun; 40(6):2869-2885. PubMed ID: 37133647
[TBL] [Abstract][Full Text] [Related]
15. Estimated glomerular filtration rate variability and risk of end-stage renal disease among patients with Stage 3 chronic kidney disease.
Perkins RM; Kirchner HL; Hartle JE; Bucaloiu ID
Clin Nephrol; 2013 Oct; 80(4):256-62. PubMed ID: 23993165
[TBL] [Abstract][Full Text] [Related]
16. Association of kidney disease outcomes with risk factors for CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) study.
Yang W; Xie D; Anderson AH; Joffe MM; Greene T; Teal V; Hsu CY; Fink JC; He J; Lash JP; Ojo A; Rahman M; Nessel L; Kusek JW; Feldman HI;
Am J Kidney Dis; 2014 Feb; 63(2):236-43. PubMed ID: 24182662
[TBL] [Abstract][Full Text] [Related]
17. Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease.
Taneja S; Duseja A; De A; Mehta M; Ramachandran R; Kumar V; Kohli HS; Gupta KL; Dhiman RK; Chawla Y
Dig Dis Sci; 2018 May; 63(5):1334-1340. PubMed ID: 29484572
[TBL] [Abstract][Full Text] [Related]
18. Association between Monocyte Count and Risk of Incident CKD and Progression to ESRD.
Bowe B; Xie Y; Xian H; Li T; Al-Aly Z
Clin J Am Soc Nephrol; 2017 Apr; 12(4):603-613. PubMed ID: 28348030
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study.
Butt AA; Ren Y; Puenpatom A; Arduino JM; Kumar R; Abou-Samra AB
Aliment Pharmacol Ther; 2018 Jul; 48(1):35-43. PubMed ID: 29797514
[TBL] [Abstract][Full Text] [Related]
20. Advanced chronic kidney disease, end-stage renal disease and renal death among HIV-positive individuals in Europe.
Ryom L; Kirk O; Lundgren JD; Reiss P; Pedersen C; De Wit S; Buzunova S; Gasiorowski J; Gatell JM; Mocroft A;
HIV Med; 2013 Sep; 14(8):503-8. PubMed ID: 23590641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
